Study of Pamiparib in Newly Diagnosed and rGBM

• ClinicalTrials.gov Identifier: NCT04614909
• Recruitment Status: Recruiting
• First Posted: November 4, 2020
• Last Update Posted: March 8, 2023
• Sponsor: Nader Sanai
• Collaborators: Barrow Neurological Institute; Ivy Brain Tumor Center; BeiGene
• Information provided by (Responsible Party): Nader Sanai, St. Joseph's Hospital and Medical Center, Phoenix

Study Description

Brief Summary:

This is an open-label, single-center Phase 0/2 study that will enroll up to 30 participants with newly diagnosed (N=12) and recurrent glioblastoma (N=18). The trial will be composed of a Phase 0 component (subdivided into Arm A, Arm B, and Arm C), and an Exploratory Phase 2 component. Participants with tumors demonstrating a PK response in the Phase 0 component of the study will graduate to an exploratory Phase 2 component that combines therapeutic dosing of pamiparib plus fractionated radiotherapy (for unmethylated MGMT promoter newly-diagnosed cases), pamiparib plus fractionated radiotherapy (for recurrent cases) or Olaparib plus fractionated radiotherapy (recurrent cases).

Condition or disease	Intervention/treatment	Phase
Glioblastoma; Glioblastoma Multiforme; Glioblastoma Multiforme, Adult	Drug: Pamiparib; Drug: Olaparib; Radiation: Radiation therapy; Drug: Temozolomide	Early Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 30 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 0/2 Clinical Trial of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma Patients
• Actual Study Start Date: January 11, 2021
• Estimated Primary Completion Date: July 2023
• Estimated Study Completion Date: December 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm A Newly diagnosed glioblastoma treated with pamiparib- ARM CLOSED; Participants undergoing resection for a presumed newly diagnosed glioblastoma (nGBM) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.	Drug: Pamiparib; 60mg administered orally BID for 4 days prior to surgical resection; Radiation: Radiation therapy; Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care; Drug: Temozolomide; Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.
Experimental: Arm B Recurrent glioblastoma treated with pamiparib; Recurrent glioblastoma (rGBM) patients who are scheduled for surgery and expected to receive postoperative fractionated radiotherapy (RT) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.	Drug: Pamiparib; 60mg administered orally BID for 4 days prior to surgical resection; Radiation: Radiation therapy; Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care; Drug: Temozolomide; Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.
Experimental: Arm C Recurrent glioblastoma treated with olaparib - ARM CLOSED; Arm C will be an exploratory arm in recurrent glioblastoma patients (rGBM) treated with Olaparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive olaparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.	Drug: Olaparib; 200mg administered orally BID for 4 days prior to surgical resection; Radiation: Radiation therapy; Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care; Drug: Temozolomide; Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.

Outcome Measures

Primary Outcome Measures :

1. Systemic plasma PK profile parameters [ Time Frame: Day 4 Intra-operative sample ]
   Total and unbound pamiparib concentration in enhancing and non-enhancing tumor tissue.

Secondary Outcome Measures :

1. Progression-free survival in participants with demonstrated PK effects [ Time Frame: 6 months ]
   6-month progression-free survival (PFS6) rate measured from time of surgery to date of recurrence
2. Overall survival [ Time Frame: 24 months ]
   Median overall survival
3. Drug-related toxicity [ Time Frame: 24 months ]
   Incidence of drug-related toxicity
4. Adverse events [ Time Frame: 24 months ]
   Number of Adverse Events through study completion, assessed up to 24 months
5. Treatment-emergent adverse events [ Time Frame: 24 months ]
   Number of treatment-emergent adverse events
6. Deaths [ Time Frame: 24 months ]
   Number and incidence of deaths
7. Pharmacodynamics (PD) of pamiparib [ Time Frame: Day 4 Intra-operative sample ]
   Quantification of PAR concentration in tumor homogenates

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Participants undergoing resection for a suspected newly diagnosed glioblastoma who are also planned to follow the standard regimen or;
2. Participants who have had a prior resection of histologically diagnosed glioblastoma (WHO grade IV), defined as participants who have progressed on or following standard therapy, which includes maximal surgical resection, temozolomide, and fractionated radiotherapy. Participants will also need to have radiation planned as part of the post-surgical treatment plan.
3. Participants must have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm.
4. Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable).
5. Participant has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative(s), and assent if applicable). Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.
6. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other procedures.
7. Age ≥18 at time of consent
8. Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology (Group (ECOG) scale (Oken et al. 1982)
9. Ability to swallow oral medications.
10. Participant has adequate bone marrow and organ function
11. Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause.
12. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to treatment and agreement to use such a method during study participation and for an additional 6 months after the end of treatment administration.
13. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner and for an additional 6 months after the end of treatment administration. Avoid sperm donation for duration of the study and for an additional 6 months after the end of treatment administration.
14. Agreement to adhere to Lifestyle Considerations throughout study duration.
15. Participants who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to Day 1. A washout period of at least 21 days is required between last chemotherapy dose and Day 1 (provided the participant did not receive radiotherapy).
16. Females of child-bearing potential must agree not to breastfeed starting at screening, throughout the study period and for 6 months after final study drug administration

Exclusion Criteria:

1. Current use of coumarin-derived anticoagulant for treatment, prophylaxis or otherwise, that cannot be discontinued prior to surgery. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed.
2. Pregnancy or lactation.
3. Known allergic reactions to components of the pamiparib capsule/olaparib.
4. Active infection or fever >38.5°C requiring systemic antibiotic, antifungal or antiviral therapy within 4 weeks of Day 1.
5. Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis.
6. Known active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.

7. Any of the following cardiovascular criteria:

   • Current evidence of cardiac ischemia
   • Current symptomatic pulmonary embolism
   • Acute myocardial infarction ≤ 6 months prior to Day 1
   • Heart failure of New York Heart Association Classification III or IV (see Section 13.2) ≤ 6 months prior to Day 1
   • Grade ≥ 2 ventricular arrhythmia ≤ 6 months prior to Day 1
   • Cerebral vascular accident (CVA) or transient ischemic attack (TIA) ≤ 6 months prior to Day 1
8. Participant has myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML
9. Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
10. Prior therapy with PARP inhibitors.
11. Treatment with another investigational drug or other intervention within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.
12. For Olaparib participants: Use or anticipated need for food and drugs known to be strong or moderate CYP3A inducers or inhibitors ≤10 days (or ≤5 half-lives, whichever is the shorter) prior to day 1.

Contacts and Locations

Locations

United States, Arizona

St. Joseph's Hospital and Medical Center; Recruiting

Phoenix, Arizona, United States, 85013

Contact: Phase 0 Navigator 602-406-8605 research@ivybraintumorcenter.org

Principal Investigator: Nader Sanai, MD

Sponsors and Collaborators

Nader Sanai

Barrow Neurological Institute

Ivy Brain Tumor Center

BeiGene

More Information

• Responsible Party: Nader Sanai, Deputy Director, Ivy Brain Tumor Center, St. Joseph's Hospital and Medical Center, Phoenix
• ClinicalTrials.gov Identifier: NCT04614909
• Other Study ID Numbers: 2020-12
• First Posted: November 4, 2020
• Last Update Posted: March 8, 2023
• Last Verified: March 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Glioblastoma; Astrocytoma; Glioma; Temozolomide; Olaparib; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Poly(ADP-ribose) Polymerase Inhibitors; Enzyme Inhibitors